摘要
目的探讨低分子肝素钙联合山莨菪碱治疗早发型重度子痫前期的临床疗效。方法选取2011年6月—2017年6月在西北妇女儿童医院治疗的早发型重度子痫前期患者156例为研究对象,随机分为对照组(78例)和治疗组(78例))。对照组患者肌内注射盐酸消旋山莨菪碱注射液,10 mg/次,2次/d。治疗组在对照组的基础上腹壁皮下注射低分子肝素钙注射液,2 050 AXa IU/次,2次/d。两组患者连续治疗1周。比较两组的血压、肾功能指标、妊娠结局及妊娠并发症情况。结果治疗后,对照组收缩压和平均动脉压明显下降,治疗组收缩压、舒张压和平均动脉压均明显下降,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组患者舒张压和平均动脉压水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者24 h尿蛋白、尿酸(UA)、尿素氮(BUN)、血肌酐(Scr)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗组患者比对照组降低更明显,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者的新生儿体质量、存活数、分娩孕周和延长孕龄天数均明显优于对照组患者,两组比较差异具有统计学意义(P<0.05)。对照组和治疗组并发症的发生率分别为15.18%、7.59%,两组比较差异具有统计学意义(P<0.05)。结论低分子肝素钙联合山莨菪碱治疗早发型重度子痫前期具有较好的临床疗效,具有一定的临床推广应用价值。
Objective To explore the clinical efficacy of low molecular weight heparin calcium combined with anisodamine in treatment of early onset severe preeclampsia. Methods Patients（156 cases） with early onset severe preeclampsia in Northwest Women and Children Hospital from June 2011 to June 2017 were randomly divided into control（78 cases） and treatment（78 cases） groups. Patients in the control group were intramuscular injection administered with Raceanisodamine Hydrochloride Injection, 10 mg/time, twice daily. Patients in the treatment group were abdominal subcutaneous injection administered with Low-Molecular-Weight Heparins Calcium Injection on the basis of the control group, 2 050 AXa IU/time, twice daily. Patients in two groups were treated for 1 week. After treatment, blood pressure, renal function, pregnancy and pregnancy complications in two groups before and after treatment were compared. Results After treatment, the systolic pressure and mean arterial pressure in the control group was significantly decreased, the systolic pressure, diastolic pressure and mean arterial pressure in the treatment group was also significantly decreased, and there were differences in the same group（P〈0.05）. And the diastolic pressure and mean arterial pressure in the treatment group was significantly lower than that in the control group, with significant difference between two groups（P〈0.05）. After treatment, the 24 h urine protein, UA, BUN, and Scr levels in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And these indicators in the treatment group were significantly lower than that in the control group, with significant difference between two groups（P〈0.05）. After treatment, the body mass of newborns, survival cases, childbirth week, and pregnant duration prolonging in the treatment group was significantly better than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the incidence of complications in the control and treatment groups were 15.18% and 7.59%, respectively, and there were differences between two groups（P〈0.05）. Conclusion Low molecular weight heparin calcium combined with anisodamine has good clinical efficacy in treatment of early onset severe preeclampsia, which has a certain clinical application value.
出处
《现代药物与临床》
CAS
2017年第12期2461-2464,共4页
Drugs & Clinic
关键词
低分子肝素钙注射液
盐酸消旋山莨菪碱注射液
早发型重度子痫前期
血压
肾功能
妊娠
Low-Molecular-Weight Heparins Calcium Injection
Raceanisodamine Hydrochloride Injection
early onset severe preeclampsia
blood pressure
renal function
pregnancy
